Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2022

View Archived Issues

The enzyme NOX4 is essential for the antidiabetes effect of exercise

YAP1 promotes salivary gland regeneration after injury

Novel inhibitors of fungal FA biosynthesis show broad-spectrum antifungal activity

Medshine Discovery discloses EZH2 inhibitors

Leo Pharma patents IL-17 modulators

Chinese researchers synthesize new SOS1 inhibitors

Roche identifies new ENPP2 inhibitors

Arbutus Biopharma presents new HBV and/or HDV capsid assembly inhibitors

Discovery of triple-action inhibitor for the treatment of neurodegenerative diseases

uPA-uPAR blockade protects intestinal epithelial barrier from inflammation-induced damage

Novel allosteric inhibitor of tumor-promoting PPI between AIMP2-DX2 and HSP70

Ovid licenses KCC2 transporter activators from AstraZeneca

Jemincare's JMB-2002 retains efficacy against Omicron variant of SARS-CoV-2

German grant supports Evotec's development of EVT-075 for COVID-19

Amberstone Biosciences completes financing round to support immuno-oncology pipeline

PLCbeta4 blockade is a potential approach for treating uveal melanoma

Ascletis announces new oral direct-acting antivirals being developed for SARS-CoV-2 infection

Kyverna licenses CAR T construct for use in autologous and allogeneic therapies

Garvan Institute awarded grant to investigate new treatment approach for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...